Breaking News

HCATS, Apceth Expand Manufacturing Pact with Bluebird Bio

Enter long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies.

By: Contract Pharma

Contract Pharma Staff

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including: •    Late stage drug product manufacturing at facilities in Germany (apceth) and the U.S. (HCATS) for bluebird bio’s LentiGlobin for the treatment of sickle cell disease (SCD) and commercial drug product manufactu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters